Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappa B-inducing kinase-specific siRNA using liver-targeting liposomes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Hyun-Ah | - |
dc.contributor.author | Park, In-Sung | - |
dc.contributor.author | Kim, Tae-Woo | - |
dc.contributor.author | Oh, Yu-Kyoung | - |
dc.contributor.author | Yang, Ki-Sook | - |
dc.contributor.author | Kim, Jin-Seok | - |
dc.date.available | 2021-02-22T14:16:57Z | - |
dc.date.issued | 2009-07 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/13731 | - |
dc.description.abstract | Hepatitis B virus triggers an increase of NF-kappa B inducing kinase (NIK)-dependent NF-kappa B activation, followed by the promotion of hepatocellular carcinoma (HCC). Here, we examined the inhibitory effect of NIK-specific siRNA on NF-kappa B signaling and HCC. The results of this study indicated that these siRNAs suppressed HBV-derived HCC by regulating NIK activation. To exert a protective effect from degradation enzyme, cationic liposomes were contrived and modified to contain beta-sitosterol glucoside to target the asialoglycoprotein receptors in liver cancer cells. The cationic dimyristoyl diacyltrimethylammonium propane liposomes were prepared by a reverse-phase evaporation method with slight modification. beta-Sitosterol glucoside was added to the lipid mixture at the beginning of the liposome preparation for the purpose of liver targeting. These liposomes assisted the delivery of the siRNA to specific cells and protected it from various lyases, followed by the ultimate suppression of HCC. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappa B-inducing kinase-specific siRNA using liver-targeting liposomes | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.1007/s12272-009-1714-z | - |
dc.identifier.scopusid | 2-s2.0-68649120934 | - |
dc.identifier.wosid | 000268511000016 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.32, no.7, pp 1077 - 1086 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 32 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1077 | - |
dc.citation.endPage | 1086 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001364388 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | RNA INTERFERENCE | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | BETA | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | SIGNAL | - |
dc.subject.keywordPlus | ALPHA | - |
dc.subject.keywordAuthor | siRNA | - |
dc.subject.keywordAuthor | DMTAP | - |
dc.subject.keywordAuthor | Beta-sitosterol glucoside | - |
dc.subject.keywordAuthor | Liposomes | - |
dc.subject.keywordAuthor | Hepatitis B Virus | - |
dc.subject.keywordAuthor | NF-kappa B-inducing kinase | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.